Research Analysts Set Expectations for STOK FY2030 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at HC Wainwright issued their FY2030 EPS estimates for Stoke Therapeutics in a research note issued to investors on Friday, March 20th. HC Wainwright analyst A. Ghosh forecasts that the company will earn $4.03 per share for the year. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

A number of other brokerages have also commented on STOK. Wall Street Zen lowered Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. BTIG Research restated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a report on Thursday, March 19th. Chardan Capital reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 18th. UBS Group set a $50.00 price target on Stoke Therapeutics in a report on Monday, December 15th. Finally, Wedbush lifted their price target on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $41.83.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $33.40 on Monday. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $40.22. The stock’s 50-day moving average is $32.69 and its two-hundred day moving average is $30.26. The firm has a market cap of $1.98 billion, a P/E ratio of 49.85 and a beta of 1.07.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. AQR Capital Management LLC boosted its position in shares of Stoke Therapeutics by 1.2% in the fourth quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock valued at $935,000 after acquiring an additional 354 shares during the period. Strs Ohio increased its position in Stoke Therapeutics by 9.4% during the fourth quarter. Strs Ohio now owns 7,000 shares of the company’s stock worth $222,000 after acquiring an additional 600 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Stoke Therapeutics by 31.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock valued at $88,000 after purchasing an additional 658 shares during the last quarter. Generali Investments Management Co LLC raised its stake in Stoke Therapeutics by 41.0% during the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company’s stock valued at $78,000 after purchasing an additional 718 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in Stoke Therapeutics in the 4th quarter valued at $26,000.

Insiders Place Their Bets

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 4,628 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $145,041.52. Following the sale, the general counsel owned 28,836 shares of the company’s stock, valued at $903,720.24. This trade represents a 13.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Barry Ticho sold 6,686 shares of Stoke Therapeutics stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $209,539.24. Following the completion of the transaction, the insider directly owned 40,798 shares in the company, valued at approximately $1,278,609.32. This represents a 14.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 69,699 shares of company stock valued at $2,526,714 in the last ninety days. Company insiders own 9.50% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.